A tooth whitening and tooth strengthening method is disclosed which is harmless to the human body and with which it is possible to remove dental plaques, tartars, coloring components and organic pellicles, promote calcification, repair the surface of teeth by reconstruction of enamel, whiten teeth and prevent caries.

The tooth whitening and tooth strengthening method first applies acid solvents such as citric acid, acetic acid, malic acid, malic acid or ascorbic acid with a pH of 0.5 to 5.0. to the surface of teeth as a first stage of treatment, applies hydroxyapatite which is dissolved in saliva or saliva-like solvent as a second stage, and then applies fluoride as a third stage.

An oral mucosal carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active agent.

An oral mucosal carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active agent.

A microcapsule composition comprising at least one polymer substantially disposed as a semipermeable shell around an aqueous buffered solution and at least one agent, wherein the agent permeates the shell, and wherein the composition is suitable for delivery to a mammal.

A microcapsule composition comprising at least one polymer substantially disposed as a semipermeable shell around an aqueous buffered solution and at least one agent, wherein the agent permeates the shell, and wherein the composition is suitable for delivery to a mammal.

Disclosed is inhaling or spraying sodium fluoride (NaF) or other fluoride salts, e.g., stannous fluoride, potassium fluoride, calcium fluoride, or magnesium fluoride, or other fluoride compounds, e.g., sodium monofluoro phosphate, in solution or in emulsion (carried in, e.g., a lipid phase) or where the solution or emulsion is encapsulated in microparticles into the mouth region and/or nasal cavities for treatment or prophylaxis of viral infections, including SARS-CoV-2 and other corona viruses, influenza, parainfluenza and rhinoviruses (which are the primary agents responsible for common colds) and other human and animal respiratory pathogenic viruses.

Disclosed is inhaling or spraying sodium fluoride (NaF) or other fluoride salts, e.g., stannous fluoride, potassium fluoride, calcium fluoride, or magnesium fluoride, or other fluoride compounds, e.g., sodium monofluoro phosphate, in solution or in emulsion (carried in, e.g., a lipid phase) or where the solution or emulsion is encapsulated in microparticles into the mouth region and/or nasal cavities for treatment or prophylaxis of viral infections, including SARS-CoV-2 and other corona viruses, influenza, parainfluenza and rhinoviruses (which are the primary agents responsible for common colds) and other human and animal respiratory pathogenic viruses.

A microcapsule composition comprising at least one polymer substantially disposed as a semipermeable shell around a buffered solution and at least one therapeutic agent, wherein the therapeutic agent permeates the shell, and wherein the composition is suitable for topical epithelial cells of mammal.

A microcapsule composition comprising at least one polymer substantially disposed as a semipermeable shell around a buffered solution and at least one therapeutic agent, wherein the therapeutic agent permeates the shell, and wherein the composition is suitable for topical epithelial cells of mammal.

A microcapsule composition comprising at least one polymer substantially disposed as a semipermeable shell around a buffered solution and at least one therapeutic agent, wherein the therapeutic agent permeates the shell, and wherein the composition is suitable for topical epithelial cells of mammal.